UPC_CFI_124/2024

TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Provisional measuresProvisional MeasuresHamburg LDProvisional measuresCase Closed

Overview Decisions Reasoning Citations Documents Timeline

Parties

Claimants

Alexion Pharmaceuticals, Inc.(AstraZeneca Group)

Reps: Elena Hennecke

Respondents

Amgen Technology (Ireland) Unlimited Company(Amgen Group)

Judges

Sabine Klepsch
Alima Zana
Stefan Schilling
Rudi Goedeweeck

Patents

EP3167888

CPC codes: A61P31/04, A61P25/18, A61P29/02, A61K39/395, A61K2039/505, A61P7/02, A61P25/26, A61P13/02, A61P15/10, A61P17/00, A61P7/00, A61P25/28…

Sector: Organic Chemistry

Outcome

PI denied

Filed: Mar 19, 2024

First decided: Jun 26, 2024

Language: English

The Hamburg Local Division dismissed Alexion Pharmaceuticals' application for a preliminary injunction against multiple Amgen entities based on EP 3 167 888, holding that while infringement could be established the court lacked sufficient certainty of patent validity given the EPO's repeated rejection of sequence correction attempts for SEQ ID NO:4.

Open on UPC Registry